Publications

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.

Life Saving Drugs Program – Fabry disease – Medicines review summary

About this resource

Publication date:
Publication type:
Procedure
Audience:
General public
Language:
English
Part of a collection:
Life Saving Drugs Program resources – Fabry disease
Tags: 

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.